FIELD: medicine.
SUBSTANCE: invention relates to biotechnology. A synthetic optionally modified oligonucleotide is described, with length of 10-30 nucleotides or 19-30 nucleotides, wherein the modification is selected from a modified sugar fragment; modified internucleotide bond; modified nucleotide, and combinations thereof. At that, the said oligonucleotide is an antisense compound that hybridizes with natural antisense polynucleotide having SEQ ID NO:3, and causes stimulation of erythropoietin gene expression. A method is also disclosed for stimulation of erythropoietin polynucleotide expression, having the sequence SEQ ID NO:1 or 2 in patient's cells or tissues, comprising application of the described oligonucleotide. A method is also disclosed for stimulation of erythropoietin gene expression in mammalian tissues or cells in vivo or in vitro, comprising bringing the said cells or tissues in contact with at least one siPHK oligonucleotide, 19-30 nucleotides in length, wherein at least one said siPHK oligonucleotide is specific against the natural antisense erythropoietin polynucleotide selected from SEQ ID NO: 3. A composition is provided for stimulation of erythropoietin gene expression in cells or tissues of a mammal comprising one or more oligonucleotide described and a pharmaceutically acceptable excipient.
EFFECT: invention expands the arsenal of treatment of diseases associated with erythropoietin.
25 cl, 6 dwg, 5 ex
